Therapies for multiple sclerosis: considerations in the pediatric patient (Q37827690)

23 August 2017

1 reference

title

Therapies for multiple sclerosis: considerations in the pediatric patient (English)

1 reference

23 August 2017

0 references

1 reference

3

Gavin Giovannoni

1 reference

23 August 2017

2

Amit Bar-Or

1 reference

23 August 2017

Brenda Banwell

1

1 reference

23 August 2017

Russell C Dale

series ordinal

4

1 reference

23 August 2017

Marc Tardieu

series ordinal

5

1 reference

23 August 2017

language of work or name

English

0 references

publication date

11 January 2011

1 reference

23 August 2017

Nature Reviews Neurology

1 reference

23 August 2017

7

1 reference

23 August 2017

2

1 reference

23 August 2017

109-122

1 reference

https://scigraph.springernature.com/pub.10.1038/nrneurol.2010.198

23 August 2017

0 references

cites work

Increased relapse rate in pediatric-onset compared with adult-onset multiple sclerosis

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.198

The management of multiple sclerosis in children: a European view

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.198

Treatment of pediatric multiple sclerosis and variants

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.198

Pediatric central nervous system inflammatory demyelination: acute disseminated encephalomyelitis, clinically isolated syndromes, neuromyelitis optica, and multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.198

Clinical outcome of children presenting with a severe manifestation of acute disseminated encephalomyelitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.198

Multiple sclerosis in children: clinical diagnosis, therapeutic strategies, and future directions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.198

Clinical features and viral serologies in children with multiple sclerosis: a multinational observational study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.198

Clinical characteristics and long term prognosis in early onset multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.198

Multiple sclerosis in childhood: clinical features of 149 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.198

Prospective study of multiple sclerosis with early onset

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.198

Prognostic factors for early severity in a childhood multiple sclerosis cohort.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.198

Natural history of multiple sclerosis with childhood onset.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.198

Difference in disease burden and activity in pediatric patients on brain magnetic resonance imaging at time of multiple sclerosis onset vs adults.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.198

Consensus definitions proposed for pediatric multiple sclerosis and related disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.198

Epstein-Barr virus in pediatric multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.198

Environmental risk factors for multiple sclerosis. Part I: The role of infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.198

The immunology of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.198

A full genome search in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.198

Risk alleles for multiple sclerosis identified by a genomewide study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.198

Magnetic resonance imaging characteristics of children and adults with paediatric-onset multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.198

Younger children with MS have a distinct CSF inflammatory profile at disease onset

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.198

Age-dependent B cell autoimmunity to a myelin surface antigen in pediatric multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.198

High seroprevalence of Epstein-Barr virus in children with multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.198

Parental smoking at home and the risk of childhood-onset multiple sclerosis in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.198

Multiple sclerosis: the environment and causation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.198

Ontogeny of the allergic inflammatory response

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.198

Human immune development: implications for congenital HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.198

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.198

Familial hemophagocytic lymphohistiocytosis: clinical and neuroradiological findings and review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.198

Aicardi-Goutieres syndrome and related phenotypes: linking nucleic acid metabolism with autoimmunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.198

Opsoclonus-myoclonus in children associated or not with neuroblastoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.198

N-methyl-D-aspartate receptor antibodies in pediatric dyskinetic encephalitis lethargica

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.198

Role of perinatal inflammation in cerebral palsy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.198

Innate immunity of the newborn: basic mechanisms and clinical correlates

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.198

Abnormal T-cell reactivities in childhood inflammatory demyelinating disease and type 1 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.198

Self-antigen tetramers discriminate between myelin autoantibodies to native or denatured protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.198

For neonates undergoing cardiac surgery does thymectomy as opposed to thymic preservation have any adverse immunological consequences?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.198

Innate and adaptive immunosenescence

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.198

Central nervous system involvement in pediatric rheumatic diseases: current concepts in treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.198

The effectiveness of treating juvenile dermatomyositis with methotrexate and aggressively tapered corticosteroids

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.198

New treatment strategies for proliferative lupus nephritis: keep children in mind!

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.198

First episode of acute CNS inflammatory demyelination in childhood: prognostic factors for multiple sclerosis and disability.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.198

The natural history of multiple sclerosis: a geographically based study 10: relapses and long-term disability

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.198

Examination of the role of magnetic resonance imaging in multiple sclerosis: A problem-orientated approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.198

Environmental risk factors for multiple sclerosis. Part II: Noninfectious factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.198

Past exposure to sun, skin phenotype, and risk of multiple sclerosis: case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.198

Vitamin D levels in people with multiple sclerosis and community controls in Tasmania, Australia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.198

A phase I/II dose-escalation trial of vitamin D3 and calcium in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.198

Short- and long-term safety of weekly high-dose vitamin D3 supplementation in school children.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.198

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.198

Estimates of optimal vitamin D status

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.198

Intravenous immunoglobulin therapy in acute disseminated encephalomyelitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.198

Immunomodulatory treatment of early onset multiple sclerosis: results of an Italian Co-operative Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.198

Long-term results of immunomodulatory treatment in children and adolescents with multiple sclerosis: the Italian experience.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.198

Disease-modifying drugs in childhood-juvenile multiple sclerosis: results of an Italian co-operative study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.198

Recommendations for clinical use of data on neutralising antibodies to interferon-beta therapy in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.198

Key issues in the diagnosis and treatment of multiple sclerosis. An overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.198

Acquired sexual paraphilia in patients with multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.198

A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.198

Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.198

Anti-JC virus antibodies: implications for PML risk stratification

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.198

Mitoxantrone: benefits and risks in multiple sclerosis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.198

Revision of the risk of secondary leukaemia after mitoxantrone in multiple sclerosis populations is required.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.198

Cyclophosphamide therapy in pediatric multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.198

An experimental protocol for fertility preservation in prepubertal boys recently diagnosed with cancer: a report of acceptability and safety

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.198

Azathioprine. Safety profile in multiple sclerosis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.198

Serial combination therapy: is immune modulation in multiple sclerosis enhanced by initial immune suppression?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.198

Defining multiple sclerosis treatment response with magnetic resonance imaging: how much activity is too much?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.198

Concepts of induction and escalation therapy in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.198

Disease-modifying agents in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.198

Lymphocyte homeostasis following therapeutic lymphocyte depletion in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.198

Bone marrow transplantation: does it stop MS progression?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.198

Early highly aggressive MS successfully treated by hematopoietic stem cell transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.198

Rituximab in relapsing-remitting multiple sclerosis: a 72-week, open-label, phase I trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.198

B-cell depletion with rituximab in relapsing-remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.198

Modern therapeutic strategies for paediatric systemic lupus erythematosus and lupus nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.198

Progressive multifocal leucoencephalopathy in the rheumatic diseases: assessing the risks of biological immunosuppressive therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.198

Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.198

Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.198

FTY720 modulates human oligodendrocyte progenitor process extension and survival.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.198

Thymic emigration: sphingosine-1-phosphate receptor-1-dependent models and beyond

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.198

Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.198

A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.198

Distinct properties of circulating CD8+ T cells in FTY720-treated patients with multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.198

Reconstitution of circulating lymphocyte counts in FTY720-treated MS patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.198

Disruption of the interaction of T cells with antigen-presenting cells by the active leflunomide metabolite teriflunomide: Involvement of impaired integrin activation and immunologic synapse formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.198

Emerging therapies in relapsing-remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.198

Treatment options for multiple sclerosis: current and emerging therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.198

Child vs adult randomized controlled trials in specialist journals: a citation analysis of trends, 1985-2005.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.198

Pediatric drug labeling: improving the safety and efficacy of pediatric therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.198

Treatment of childhood acute lymphoblastic leukaemia: present issues and future prospects

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.198

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.198

Cognitive and psychosocial features of childhood and juvenile MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.198

The cognitive burden of multiple sclerosis in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.198

Cognitive functioning in children and adolescents with multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.198

School performance in a cohort of children with CNS inflammatory demyelination.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.198

Magnetic resonance imaging as a potential surrogate for relapses in multiple sclerosis: a meta-analytic approach.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.198

Defining interferon beta response status in multiple sclerosis patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.198

Prediction of neuropsychological impairment in multiple sclerosis: comparison of conventional magnetic resonance imaging measures of atrophy and lesion burden.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.198

Regional hippocampal atrophy in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.198

Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.198

Natalizumab drug holiday in multiple sclerosis: poorly tolerated

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.198

Clinical characteristics of multiple sclerosis with early onset

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.198

Glatiramer acetate treatment in patients with childhood and juvenile onset multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.198

Clinical course and prognosis of 27 patients with childhood onset multiple sclerosis in Japan.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.198

Lesion distribution in children with clinically isolated syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.198

Induction of antigen-specific tolerance in multiple sclerosis after immunization with DNA encoding myelin basic protein in a randomized, placebo-controlled phase 1/2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.198

Relationship between MRI lesion activity and response to IFN-β in relapsing–remitting multiple sclerosis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.198

Safety and efficacy of natalizumab in children with multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.198

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.198

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.198

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.198

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.198

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.198

MRI in the diagnosis of pediatric multiple sclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.198

CSF characteristics in early-onset multiple sclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.198

Neonatal adaptive immunity comes of age

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.198

Myelin basic protein-reactive autoantibodies in the serum and cerebrospinal fluid of multiple sclerosis patients are characterized by low-affinity interactions

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.198

Anti-myelin antibodies modulate clinical expression of childhood multiple sclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.198

Impact of interferon beta-1a on neurologic disability in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.198

Safety of vitamin D3 in adults with multiple sclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.198

Hypovitaminosis D in healthy schoolchildren

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.198

Wintertime vitamin D insufficiency is common in young Canadian women, and their vitamin D intake does not prevent it

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.198

Assessment of evidence for a protective role of vitamin D in multiple sclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.198

31 March 2020

The birth of bioethics.

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.198

Effects of different doses of oral cholecalciferol on serum 25(OH)D, PTH, calcium and bone markers during fall and winter in schoolchildren

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.198

Corticosteroids or ACTH for acute exacerbations in multiple sclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.198

Intravenous gammaglobulin therapy in recurrent acute disseminated encephalomyelitis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.198

Experiences of children and adolescents living with multiple sclerosis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.198

Interferon beta-1a treatment in childhood and juvenile-onset multiple sclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.198

Safety and tolerability of interferon beta-1b in pediatric multiple sclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.198

Effectiveness of early beta interferon on the first attack after confirmed multiple sclerosis: a comparative cohort study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.198

Interferon beta-1a in children with multiple sclerosis is well tolerated

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.198

Early onset multiple sclerosis: a longitudinal study.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.198

Natalizumab use in pediatric multiple sclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.198

Natalizumab treatment in pediatric multiple sclerosis: a case report

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.198

Azathioprine for multiple sclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.198

Differential responses of human microglia and blood-derived myeloid cells to FTY720.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.198

Antigen-specific therapies in multiple sclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.198

Ensuring safe and effective medications for children

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.198

Randomized controlled trials and pediatric research

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.198

Interferon-beta treatment in patients with childhood-onset multiple sclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.198

Treatment of early onset multiple sclerosis with subcutaneous interferon beta-1a

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.198

American Academy of Pediatrics. Committee on Nutrition. Calcium requirements of infants, children, and adolescents

31 March 2020

1 reference

12 December 2020

The Canadian cooperative trial of cyclophosphamide and plasma exchange in progressive multiple sclerosis. The Canadian Cooperative Multiple Sclerosis Study Group

1 reference

12 December 2020

Treatment of multiple sclerosis with anti-CD20 antibodies

1 reference

12 December 2020

Isolated demyelinating syndromes: comparison of different MR imaging criteria to predict conversion to clinically definite multiple sclerosis

1 reference

12 December 2020

HLA-DRB1 confers increased risk of pediatric-onset MS in children with acquired demyelination

1 reference

12 December 2020

MRI correlates of cognitive impairment in childhood-onset multiple sclerosis

1 reference

12 December 2020

BHT-3009, a myelin basic protein-encoding plasmid for the treatment of multiple sclerosis

1 reference

12 December 2020

Vitamin D status is associated with relapse rate in pediatric-onset multiple sclerosis

1 reference

12 December 2020

Vitamin D supplementation: Recommendations for Canadian mothers and infants

1 reference

12 December 2020

10.1038/NRNEUROL.2010.198

Identifiers

DOI

1 reference

Dimensions Publication ID

23 August 2017

0 references

1 reference